ReviewJournal of cardiovascular development and disease2026
Colchicine in Coronary Artery Disease-Too Much of a Good Thing?
Review in Journal of cardiovascular development and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD) is the leading cause of mortality and morbidity in the world. While low-density lipoprotein cholesterol has been the main target of secondary prevention, inflammation has gained traction as a potential target for reducing adverse cardiovascular events. Hence, in this review, we aim to outline the current evidence base for the use of colchicine in CAD to provide more clarity from the findings in the recent trials and meta-analyses (LoDoCo2, COLCOT, COPS, CONVINCE, CLEAR-SYNERGY, COLOCT, and EKSTROM). Given colchicine's low cost and widespread availability, it is a potential adjunct to lipid-lowering therapy. However, it may not be as effective in the secondary prevention of CAD as previously thought. Ongoing research on colchicine remains vital to determine its utility in patient populations beyond those with CAD as well as to better understand the fine balance between its therapeutic benefits and potential side effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.